Literature DB >> 30232399

Aspirin in the prevention of preeclampsia: the conundrum of how, who and when.

Renuka Shanmugalingam1,2, Annemarie Hennessy3,4, Angela Makris3,4.   

Abstract

Aspirin is widely used in preventing early onset preeclampsia in women who are identified as being high risk. Although the benefit of aspirin is increasingly evident and acknowledged, there remains many unanswered questions with regards to its optimal application in pregnancy. The issues mainly centre around the relatively modest risk reduction that is observed with the use of aspirin prophylactically. We aim to explore the reasons behind the conservative rate of benefit and aim to explore factors that are likely to influence the outcomes with the use of aspirin.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30232399     DOI: 10.1038/s41371-018-0113-7

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  65 in total

Review 1.  Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia.

Authors:  Sharon E Maynard; Shivalingappa Venkatesha; Ravi Thadhani; S Ananth Karumanchi
Journal:  Pediatr Res       Date:  2005-04-06       Impact factor: 3.756

Review 2.  Epidemiology of preeclampsia: impact of obesity.

Authors:  Arun Jeyabalan
Journal:  Nutr Rev       Date:  2013-10       Impact factor: 7.110

3.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.

Authors:  Ravi Thadhani; Henning Hagmann; Wiebke Schaarschmidt; Bernhard Roth; Tuelay Cingoez; S Ananth Karumanchi; Julia Wenger; Kathryn J Lucchesi; Hector Tamez; Tom Lindner; Alexander Fridman; Ulrich Thome; Angela Kribs; Marco Danner; Stefanie Hamacher; Peter Mallmann; Holger Stepan; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

4.  Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.

Authors:  Daniel L Rolnik; David Wright; Liona C Poon; Neil O'Gorman; Argyro Syngelaki; Catalina de Paco Matallana; Ranjit Akolekar; Simona Cicero; Deepa Janga; Mandeep Singh; Francisca S Molina; Nicola Persico; Jacques C Jani; Walter Plasencia; George Papaioannou; Kinneret Tenenbaum-Gavish; Hamutal Meiri; Sveinbjorn Gizurarson; Kate Maclagan; Kypros H Nicolaides
Journal:  N Engl J Med       Date:  2017-06-28       Impact factor: 91.245

5.  Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.

Authors:  Richard J Levine; Chun Lam; Cong Qian; Kai F Yu; Sharon E Maynard; Benjamin P Sachs; Baha M Sibai; Franklin H Epstein; Roberto Romero; Ravi Thadhani; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

6.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 7.  Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.

Authors:  Shireen Meher; Lelia Duley; Kylie Hunter; Lisa Askie
Journal:  Am J Obstet Gynecol       Date:  2016-11-01       Impact factor: 8.661

8.  Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.

Authors:  Kenji Onda; Stephen Tong; Sally Beard; Natalie Binder; Masanaga Muto; Sevvandi N Senadheera; Laura Parry; Mark Dilworth; Lewis Renshall; Fiona Brownfoot; Roxanne Hastie; Laura Tuohey; Kirsten Palmer; Toshihiko Hirano; Masahito Ikawa; Tu'uhevaha Kaitu'u-Lino; Natalie J Hannan
Journal:  Hypertension       Date:  2017-01-23       Impact factor: 10.190

9.  A1M/α1-microglobulin protects from heme-induced placental and renal damage in a pregnant sheep model of preeclampsia.

Authors:  Lena Wester-Rosenlöf; Vera Casslén; Josefin Axelsson; Anneli Edström-Hägerwall; Magnus Gram; Madlene Holmqvist; Martin E Johansson; Iréne Larsson; David Ley; Karel Marsal; Matthias Mörgelin; Bengt Rippe; Sigurbjörg Rutardottir; Behnaz Shohani; Bo Akerström; Stefan R Hansson
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates.

Authors:  Angela Makris; Kristen R Yeung; Shirlene M Lim; Neroli Sunderland; Scott Heffernan; John F Thompson; Jim Iliopoulos; Murray C Killingsworth; Jim Yong; Bei Xu; Robert F Ogle; Ravi Thadhani; S Ananth Karumanchi; Annemarie Hennessy
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

View more
  2 in total

1.  Longitudinally Tracking Maternal Autonomic Modulation During Normal Pregnancy With Comprehensive Heart Rate Variability Analyses.

Authors:  Maretha Bester; Rohan Joshi; Massimo Mischi; Judith O E H van Laar; Rik Vullings
Journal:  Front Physiol       Date:  2022-05-09       Impact factor: 4.755

Review 2.  The Involvement of MicroRNAs in SARS-CoV-2 Infection Comorbid with HIV-Associated Preeclampsia.

Authors:  Tashlen Abel; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2021-04-13       Impact factor: 5.369

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.